The latest biotech news

capella biosciences medicxi ventures advent life sciences osage university partners mabs monoclonal antibodies oncology autoimmune target biology

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

aprea ovarian cancer p53 protein apr 246 karolinska versant ventures 5am ventures healthcap

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

edna environment conservation genetics biotech freshwater biodiversity spygen newts

News and Trends 10 Mar 2016

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

This is the story of how the Natural History Museum of Denmark and Molecular Ecology biotech Spygen (France) brought together forensic science techniques to detect traces of Great Crested Newt DNA in UK ponds. The Great Crested Newt (Triturus cristatus) is an amphibian found across Northern Europe and parts of Asia, which has been declining since […]

March 10, 2016 - 3 minutesmins - By Joachim Eeckhout

prime priority medicines ema european medicine agency breakthrough therapy fast track biotech

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

wales life sciences investment fund finance wales wao £50M chris evans arthurian

News and Trends 9 Mar 2016

Significant doubts about Welsh Government handling of Biotech VC fund

The Wales Life Sciences Fund was intended to attract Biotechs and Pharma to this part of the UK – but the governmental oversight of the establishment of this £50M fund has been criticised in a report by the Wales Audit Office… [Editor’s note: this article was initially published on March 7th, 2016. Due to some inaccuracies, we […]

March 9, 2016 - 3 minutesmins - By Joachim Eeckhout

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

spark therapeutics genable gene therapy blindness pigmentosa rhonova

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

genzyme sanofi enzyme replacement therapy pompe disease neogaa neo1

News and Trends 8 Mar 2016

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Sanofi Genzyme (Boston and France) have obtained good phase I/II results with a candidate for the rare Pompe Disease and expects to move to phase III in the second quarter of 2016. Sanofi Genzyme continues to bet on rare diseases and neurodegenerative disorders, now with a therapy for late-onset Pompe Disease. Pompe Disease is a […]

March 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

crispr mimivire aix nature virus synbio biotech

News and Trends 4 Mar 2016

This Megavirus has its own CRISPR-like Defense System

MIMIVIRE is the name French researchers have given to the immunity mechanism of mimivirus, and that they have now described in a new paper for Nature. What is a mimivirus? What is viral immunity? What is life? What is CRISPR? Well, for the last question, you should read our review on CRISPR. As for the rest, […]

March 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

horizon centarui axxinity venture therapeutics alphamers cancer1

News and Trends 4 Mar 2016

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie’s Humira, to treat Chronic plaque psoriasis. This is a big deal as Humira is the best selling biologics of all time (over €10Bn in annual revenues). Merck is developing a candidate (MSB11022) as a biosimilar of adalimumab, a human monoclonal antibody sold under the brand Humira – a key […]

March 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

EMA Launches its own Fast Track for Breakthrough Therapies

Significant doubts about Welsh Government handling of Biotech VC fund

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

This Megavirus has its own CRISPR-like Defense System

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!